Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56), in which the peptide is in a complex with an MHC molecule.
1. A method of eliciting a CD8+cytotoxic T cell response in an HLA-A*02+patient who has hepatocellular carcinoma (HCC) that presents at the cell surface a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56), comprising
administering to said identified patient a composition comprising a population of activated antigen-specific CD8+cytotoxic T cells to kill the HCC cells in the identified patient,
wherein the population of activated antigen-specific CD8+cytotoxic T cells recognize the HCC cells by interacting through their TCR with a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56) in a complex with HLA-A*02 presented at the surface of the HCC cells,
wherein the activated antigen-specific CD8+cytotoxic T cells are autologous to the patient.
2. The method of claim 1 , wherein the activated antigen-specific CD8+cytotoxic T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
3. The method of claim 1 , wherein the composition further comprises an adjuvant.
4. The method of claim 3 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
5. The method of claim 4 , wherein the adjuvant is IL-2.
6. The method of claim 4 , wherein the adjuvant is IL-7.
7. The method of claim 4 , wherein the adjuvant is IL-15.
8. The method of claim 4 , wherein the adjuvant is IL-21.
9. The method of claim 4 , wherein the adjuvant is IL-12.
10. A method of eliciting a CD8+cytotoxic T cell response in an HLA-A*02+patient who has hepatocellular carcinoma (HCC), wherein the HCC cells overexpress an SLC16A11 polypeptide comprising the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56) as compared to a panel of normal tissues, wherein the HCC cells present at the cell surface a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56) in a complex with HLA-A*02, comprising
administering to said patient who has HCC a composition comprising a population of activated antigen-specific CD8+cytotoxic T cells to kill the HCC cells in the patient,
wherein the population of the activated antigen-specific CD8+cytotoxic T cells recognize the HCC cells by interacting through their TCR with a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56) in a complex with HLA-A*02 presented at the surface of the HCC cells,
wherein the activated antigen-specific CD8+cytotoxic T cells are autologous to the patient.
11. The method of claim 10 , further comprising expanding the activated T cells in vitro.
12. The method of claim 11 , wherein the expanding is in the presence of an anti-CD28 antibody and IL-12.
13. The method of claim 10 , wherein the composition further comprises an adjuvant.
14. The method of claim 13 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
15. The method of claim 14 , wherein the adjuvant is IL-7.
16. The method of claim 14 , wherein the adjuvant is IL-15.
17. The method of claim 14 , wherein the adjuvant is IL-21.
18. The method of claim 14 , wherein the adjuvant is IL-2.
19. The method of claim 10 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
20. The method of claim 10 , wherein the activated antigen-specific CD8+cytotoxic T cells are produced by contacting the CD8+cytotoxic T cells with an antigen presenting cell that present at the cell surface a peptide consisting of GVLPGLVGV (SEQ ID NO: 56) in a complex with HLA-A*02 in vitro, thereby activating the CD8+cytotoxic T cells.